ReportsnReports: Gene Therapy Partnering Terms and Agreements

Document Sample
ReportsnReports: Gene Therapy Partnering Terms and Agreements Powered By Docstoc
					Gene Therapy Partnering Terms and Agreements

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an
email on sales@reportsandreports.com with (Gene Therapy Market Partnering) /
report name in subject line and your contact details.

The Gene Therapy Partnering Agreements report provides an understanding and access to
the gene therapy partnering deals and agreements entered into by the worlds leading
healthcare companies.

      Trends in gene therapypartnering deals
      Disclosed headlines, upfronts, milestones and royalties by stage of development
      Gene therapypartnering contract documents
      Top gene therapy deals by value

Complete report of 239 Pages is available @
http://www.reportsnreports.com/reports/262461-gene-therapy-partnering-
terms-and-agreements.html.

The Gene Therapy Partnering Agreements report provides a detailed understanding and
analysis of how and why companies enter gene therapypartnering deals. The majority of
deals are early development stage whereby the licensee obtains a right or an option right to
license the licensors gene therapytechnology or product candidates. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers
agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides
critical insight into the negotiation process in terms of what you can expect to achieve
during the negotiation of terms. Whilst many smaller companies will be seeking details of
the payments clauses, the devil is in the detail in terms of how payments are triggered –
contract documents provide this insight where press releases and databases do not.




Gene Therapy Partnering Terms and Agreements
This report contains a comprehensive listing of all gene therapy partnering deals announced
since 2007 including financial terms where available including over 300 links to online deal
records of actual gene therapy partnering deals as disclosed by the deal parties. In addition,
where available, records include contract documents as submitted to the Securities
Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a
significant impact on each party’s ability to derive value from the deal.

Buy a copy of report
@ http://www.reportsnreports.com/purchase.aspx?name=262461.

OR Inquiry Before Buying on this Report @
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=262461

For example, analyzing actual company deals and agreements allows assessment
of the following:

      What is actually granted by the agreement to the partner company?
      What exclusivity is granted?
      What are the precise rights granted or optioned?
      What is the payment structure for the deal?
      How aresalesand payments audited?
      What is the deal term?
      How are the key terms of the agreement defined?
      How are IPRs handled and owned?
      Who is responsible for commercialization?
      Who is responsible for development, supply, and manufacture?
      How is confidentiality and publication managed?
      How are disputes to be resolved?
      Under what conditions can the deal be terminated?
      What happens when there is a change of ownership?
      What sublicensing and subcontracting provisions have been agreed?
      Which boilerplate clauses does the company insist upon?
      Which boilerplate clauses appear to differ from partner to partner or deal type to
       deal type?
      Which jurisdiction does the company insist upon for agreement law?




Gene Therapy Partnering Terms and Agreements
Key Benefits

Gene Therapy Partnering Terms and Agreements provides the reader with the following key
benefits:

      In-depth understanding of gene therapy deal trends since 2007
      Access to headline, upfront, milestone and royalty data
      Analysis of the structure of gene therapy agreements with numerous real life case
       studies
      Comprehensive access to over 100 actual gene therapy contracts entered into by the
       world’s biopharma companies
      Detailed access to actual gene therapy contracts enter into by the leading fifty
       bigpharma
      Insight into the terms included in gene therapy agreement, together with real world
       clause examples
      Understand the key deal terms companies have agreed in previous deals
      Undertake due diligence to assess suitability of your proposed deal terms for partner
       companies

Report scope

Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an
in-depth understanding and access to gene therapy trends and structure of deals entered
into by leading companies worldwide.

Gene Therapy Partnering Terms and Agreements includes:

      Trends in gene therapy dealmaking in the biopharma industry since 2007
      Analysis of gene therapy deal structure
      Access to headline, upfront, milestone and royalty data
      Case studies of real-life gene therapy deals
      Access to over 300 gene therapy contract documents
      The leading antibody deals by value since 2007
      Most active gene therapy dealmakers since 2007
      The leading gene therapy partnering resources

In Gene Therapy Partnering Terms and Agreements, the available contracts are
listed by:

      Company A-Z
      Headline value
      Stage of development at signing
      Deal component type
      Specific therapy and technology target


Gene Therapy Partnering Terms and Agreements
Each deal title links via Weblink to an online version of the deal record and where available,
the contract document, providing easy access to each contract document on demand.

Major Points from Table Of Contents:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in gene therapy dealmaking

Chapter 3 – Leading gene therapy deals

Chapter 4 – Bigpharma gene therapy deals

Big pharma gene therapy partnering company profiles

      Amgen
      Baxter International
      Celgene
      Daiichi Sankyo
      GlaxoSmithKline
      Merck & Co
      Mitsubishi Tanabe
      Novartis
      Pfizer
      Roche
      Sanofi
      Servier
      Takeda
      Teva

Chapter 5 – Gene therapy partnering contracts directory

Chapter 6 – Gene therapy dealmaking by technology type

Appendices

List Of Figures

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further
information on “Gene Therapy Partnering Terms and Agreements” report OR for
any other market research and intelligence needs you may have for your business.


Gene Therapy Partnering Terms and Agreements

				
DOCUMENT INFO
Description: Gene Therapy Partnering Terms and Agreements: Order report by calling ReportsnReports.com at 1 888 391 5441 OR send an email on sales@reportsandreports.com with (Gene Therapy Market Partnering) / report name in subject line and your contact details. The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. • Trends in gene therapypartnering deals • Disclosed headlines, upfronts, milestones and royalties by stage of development • Gene therapypartnering contract documents • Top gene therapy deals by value Complete report of 239 Pages is available @ http://www.reportsnreports.com/reports/262461-gene-therapy-partnering-terms-and-agreements.html. The Gene Therapy Partnering Agreements report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=262461. OR Inquiry Before Buying on this Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.